# Efficacy and Safety of Immunosuppression, Caplacizumab and Plasma Infusion Without Therapeutic Plasma Exchange in Immune-mediated Thrombotic Thrombocytopenic Purpura

> **NCT06291025** · NA · RECRUITING · sponsor: **University Hospital, Rouen** · enrollment: 131 (estimated)

## Conditions studied

- Thrombotic Microangiopathies

## Interventions

- **PROCEDURE:** PEX-FREE

## Key facts

- **NCT ID:** NCT06291025
- **Lead sponsor:** University Hospital, Rouen
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-10
- **Primary completion:** 2026-08-01
- **Final completion:** 2026-08-01
- **Target enrollment:** 131 (ESTIMATED)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06291025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06291025, "Efficacy and Safety of Immunosuppression, Caplacizumab and Plasma Infusion Without Therapeutic Plasma Exchange in Immune-mediated Thrombotic Thrombocytopenic Purpura". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06291025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*